SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has performed more than 15,000 procedures using its SSi Mantra robotic surgical systems, including approximately 750 cardiac procedures, CEO Dr. Sudhir Srivastava said in a recent interview with The Motley Fool. The disclosure, reported via NEWMEDIAWIRE, underscores the company's push to broaden access to robotic-assisted surgery across multiple specialties and geographies.
The SSi Mantra platform has also been used in more than 200 telesurgeries, including 27 cardiac procedures, as the company explores ways to extend specialist surgical expertise to underserved communities. Srivastava highlighted the system's differentiated engineering, including 4K 3D visualization, surgeon-controlled anatomical imaging, and a modular design supporting up to five robotic arms. Those features, he suggested, help explain the platform's growing adoption and its appeal to surgeons seeking flexibility in complex cases.
Commercial momentum is accelerating. SS Innovations reported first-half 2026 revenue of approximately $25 million, up about 66% year-over-year. The company is preparing to expand its Indian manufacturing capacity through a planned 10-acre facility, with the objective of bringing additional production capabilities in-house. Regulatory applications in Europe and the United States are also progressing, and management is targeting international expansion through direct sales and opportunities in ambulatory surgery centers. For a full account of the CEO's remarks, see the Read More coverage, and additional details are available through the interview summary at https://ibn.fm/EJk05.
The implications extend beyond SS Innovations. Robotic surgery systems have traditionally carried high price tags that limited adoption to well-resourced hospitals, particularly in emerging markets. By emphasizing affordability alongside advanced imaging and modular arm configurations, SS Innovations is positioning itself to compete in cost-sensitive settings where demand for minimally invasive procedures is rising. The telesurgery milestone is similarly significant: remote operations could help address shortages of specialized surgeons in rural or underserved areas, though such programs depend on reliable connectivity and appropriate regulatory oversight.
The planned 10-acre manufacturing facility in India signals a strategy to control more of the supply chain and potentially reduce costs, while pending regulatory applications in Europe and the U.S. represent key gateways to larger markets. Success in those jurisdictions would put the company in more direct competition with established robotic surgery players. For investors and industry observers, the 66% revenue growth provides evidence that adoption is translating into financial traction, though the company's forward-looking statements carry risks and uncertainties that could cause actual results to differ materially.
SS Innovations International is tracked by investors via SS Innovations International (NASDAQ: SSII), and the latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. The company's ability to convert its clinical experience into regulatory clearances and sustained revenue growth will determine whether its expansion strategy delivers on its promise.
